Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

In healthy volunteers, a monoclonal antibody fragment that binds ticagrelor and its active metabolite led to reversal of the antiplatelet effects of ticagrelor, with very few toxic effects. The presence of low titers of antibody to the active agent had no detectable effect on efficacy.